News
Glucagon-like peptide-1 receptor agonists may cut the risk of obesity-related cancer in patients being treated for diabetes and obesity.
Adults with obesity using a GLP-1 have a similar risk for obesity-related cancers as those who undergo bariatric surgery, ...
1h
The Holy Mess on MSNGLP-1 Weight Loss Drugs: Miracle, Mess, or Something in Between?Unless you are from another planet, you’ve heard all about the new weight loss medications taking the world by storm. These ...
Some of the most widely used and effective weight loss medications include: Metformin: Metformin works for weight loss by ...
The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN ...
After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk ...
While some Ozempic faces are appearing older with sunken cheeks, gaunt eyes and sagging neck skin — that doesn’t seem to be ...
Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...
India's healthtech space is expected to witness disruption as weight loss drugs Ozempic and Mounjaro enter the market through ...
Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.
Manhattan-based dentist Dr. Sandip Sachar and obesity medicine specialist Dr. Meghan Garcia-Webb discuss the prevalence of ...
Inadequate supply has created opportunities for bad actors seeking to profit from shortages, high costs and demand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results